285 related articles for article (PubMed ID: 34807369)
1. Cost-Effectiveness of Combination of Baricitinib and Remdesivir in Hospitalized Patients with COVID-19 in the United States: A Modelling Study.
Kelton K; Klein T; Murphy D; Belger M; Hille E; McCollam PL; Spiro T; Burge R
Adv Ther; 2022 Jan; 39(1):562-582. PubMed ID: 34807369
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Baricitinib Compared With Standard of Care: A Modeling Study in Hospitalized Patients With COVID-19 in the United States.
Ohsfeldt R; Kelton K; Klein T; Belger M; Mc Collam PL; Spiro T; Burge R; Ahuja N
Clin Ther; 2021 Nov; 43(11):1877-1893.e4. PubMed ID: 34732289
[TBL] [Abstract][Full Text] [Related]
3. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.
Kalil AC; Patterson TF; Mehta AK; Tomashek KM; Wolfe CR; Ghazaryan V; Marconi VC; Ruiz-Palacios GM; Hsieh L; Kline S; Tapson V; Iovine NM; Jain MK; Sweeney DA; El Sahly HM; Branche AR; Regalado Pineda J; Lye DC; Sandkovsky U; Luetkemeyer AF; Cohen SH; Finberg RW; Jackson PEH; Taiwo B; Paules CI; Arguinchona H; Erdmann N; Ahuja N; Frank M; Oh MD; Kim ES; Tan SY; Mularski RA; Nielsen H; Ponce PO; Taylor BS; Larson L; Rouphael NG; Saklawi Y; Cantos VD; Ko ER; Engemann JJ; Amin AN; Watanabe M; Billings J; Elie MC; Davey RT; Burgess TH; Ferreira J; Green M; Makowski M; Cardoso A; de Bono S; Bonnett T; Proschan M; Deye GA; Dempsey W; Nayak SU; Dodd LE; Beigel JH;
N Engl J Med; 2021 Mar; 384(9):795-807. PubMed ID: 33306283
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness Analysis of Remdesivir Treatment in COVID-19 Patients Requiring Low-Flow Oxygen Therapy: Payer Perspective in Turkey.
Oksuz E; Malhan S; Gonen MS; Kutlubay Z; Keskindemirci Y; Jarrett J; Sahin T; Ozcagli G; Bilgic A; Bibilik MO; Tabak F
Adv Ther; 2021 Sep; 38(9):4935-4948. PubMed ID: 34379304
[TBL] [Abstract][Full Text] [Related]
5. The Cost-Effectiveness of Remdesivir for Hospitalized Patients With COVID-19.
Whittington MD; Pearson SD; Rind DM; Campbell JD
Value Health; 2022 May; 25(5):744-750. PubMed ID: 35190252
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of the combination of baricitinib, remdesivir, and dexamethasone in hypoxic adults with COVID-19: A retrospective study.
Yasuda Y; Hirayama Y; Uemasu K; Arasawa S; Iwashima D; Takahashi KI
Respir Med Res; 2022 May; 81():100903. PubMed ID: 35316675
[TBL] [Abstract][Full Text] [Related]
7. Treatment of moderate to severe respiratory COVID-19: a cost-utility analysis.
Congly SE; Varughese RA; Brown CE; Clement FM; Saxinger L
Sci Rep; 2021 Sep; 11(1):17787. PubMed ID: 34493774
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of remdesivir plus usual care versus usual care alone for hospitalized patients with COVID-19: an economic evaluation as part of the Canadian Treatments for COVID-19 (CATCO) randomized clinical trial.
Lau VI; Fowler R; Pinto R; Tremblay A; Borgia S; Carrier FM; Cheng MP; Conly J; Costiniuk CT; Daley P; Duan E; Durand M; Fontela PS; Farjou G; Fralick M; Geagea A; Grant J; Keynan Y; Khwaja K; Lee N; Lee TC; Lim R; O'Neil CR; Papenburg J; Semret M; Silverman M; Sligl W; Somayaji R; Tan DHS; Tsang JLY; Weatherald J; Yansouni CP; Zarychanski R; Murthy S;
CMAJ Open; 2022; 10(3):E807-E817. PubMed ID: 36199248
[TBL] [Abstract][Full Text] [Related]
9. Mortality comparision in patients receiving either Remdesivir or Remdesivir plus Baricitinib combination in case of moderate to severe COVID-19 Pneumonia: A retrospective study.
Das D; Mukhopadhyay P; Banerjee D
J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443520
[TBL] [Abstract][Full Text] [Related]
10. Cost utility analysis of Remdesivir and Dexamethasone treatment for hospitalised COVID-19 patients - a hypothetical study.
Carta A; Conversano C
BMC Health Serv Res; 2021 Sep; 21(1):986. PubMed ID: 34537034
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of remdesivir for the treatment of severe COVID-19 patients in China under different scenarios.
Jiang Y; Cai D; Chen D; Jiang S; Si L; Wu J
Br J Clin Pharmacol; 2021 Nov; 87(11):4386-4396. PubMed ID: 33855727
[TBL] [Abstract][Full Text] [Related]
12. A Cost-Effectiveness Analysis of Remdesivir for the Treatment of Hospitalized Patients With COVID-19 in England and Wales.
Rafia R; Martyn-St James M; Harnan S; Metry A; Hamilton J; Wailoo A
Value Health; 2022 May; 25(5):761-769. PubMed ID: 35197225
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19.
Izumo T; Kuse N; Awano N; Tone M; Sakamoto K; Takada K; Muto Y; Fujimoto K; Saiki A; Ito Y; Matsumoto H; Inomata M
Respir Investig; 2021 Nov; 59(6):799-803. PubMed ID: 34413006
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
Marconi VC; Ramanan AV; de Bono S; Kartman CE; Krishnan V; Liao R; Piruzeli MLB; Goldman JD; Alatorre-Alexander J; de Cassia Pellegrini R; Estrada V; Som M; Cardoso A; Chakladar S; Crowe B; Reis P; Zhang X; Adams DH; Ely EW;
Lancet Respir Med; 2021 Dec; 9(12):1407-1418. PubMed ID: 34480861
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with remdesivir and immunomodulators improves respiratory status in COVID-19: A retrospective study.
Kojima Y; Nakakubo S; Kamada K; Yamashita Y; Takei N; Nakamura J; Matsumoto M; Horii H; Sato K; Shima H; Suzuki M; Konno S
J Med Virol; 2022 Dec; 94(12):5702-5712. PubMed ID: 35916111
[TBL] [Abstract][Full Text] [Related]
16. A Cost-Effectiveness Framework for COVID-19 Treatments for Hospitalized Patients in the United States.
Sheinson D; Dang J; Shah A; Meng Y; Elsea D; Kowal S
Adv Ther; 2021 Apr; 38(4):1811-1831. PubMed ID: 33650025
[TBL] [Abstract][Full Text] [Related]
17. Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Ren S; Bermejo I; Simpson E; Wong R; Scott DL; Young A; Stevenson M
Pharmacoeconomics; 2018 Jul; 36(7):769-778. PubMed ID: 29502174
[TBL] [Abstract][Full Text] [Related]
18. In adults hospitalized with COVID-19, adding baricitinib vs. dexamethasone to remdesivir did not differ for MV-free survival.
Tran A; Rochwerg B
Ann Intern Med; 2022 Oct; 175(10):JC115. PubMed ID: 36191322
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
[TBL] [Abstract][Full Text] [Related]
20. Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials.
Dijk SW; Krijkamp EM; Kunst N; Gross CP; Wong JB; Hunink MGM
Value Health; 2022 Aug; 25(8):1268-1280. PubMed ID: 35490085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
